EP2711024A1 — Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Assigned to United Therapeutics Corp · Expires 2014-03-26 · 12y expired
What this patent protects
A buffer solution with an effective amount of treprostinil and/or treprostinil sodium for use in the treatment of pulmonary arterial hypertension in a human subject in need thereof is provided. The buffer solution is obtainable by a process comprising diluting a starting solution…
USPTO Abstract
A buffer solution with an effective amount of treprostinil and/or treprostinil sodium for use in the treatment of pulmonary arterial hypertension in a human subject in need thereof is provided. The buffer solution is obtainable by a process comprising diluting a starting solution of treprostinil and/or treprostinil sodium with a buffer comprising glycine and having a pH of greater than 10.
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.